APGE - Apogee Therapeutics, Inc.
72.31
3.810 5.269%
Share volume: 1,354,070
Last Updated: 03-04-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.44%
PREVIOUS CLOSE
CHG
CHG%
$68.50
0.00
0.00%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | |
| Report Date | 05-13-2024 | 08-12-2024 | 11-12-2024 | 03-03-2025 | 05-12-2025 | 11-10-2025 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | ||||
| Operating expenses | 38.181 M | 44.122 M | 58.686 M | 75.881 M | 63.096 M | 71.278 M | |
| Selling general and admin | 9.465 M | 10.916 M | 12.972 M | 15.652 M | 16.709 M | 17.100 M | |
| Research and development | 28.716 M | 33.206 M | 45.714 M | 60.229 M | 46.387 M | 54.178 M | |
| Total expenses | 38.181 M | 44.122 M | 58.686 M | 75.881 M | 63.096 M | 71.278 M | |
| 15.56% | 33.01% | 29.30% | -16.85% | 12.97% | |||
| Operating income | -38.181 M | -44.122 M | -58.686 M | -75.881 M | -63.096 M | -71.278 M | |
| Ebit | -38.181 M | -44.122 M | -58.686 M | -75.881 M | -63.096 M | -71.278 M | |
| Pretax income | -32.094 M | -33.816 M | -49.018 M | -67.200 M | -55.256 M | -64.960 M | |
| 5.37% | 44.96% | 37.09% | -17.77% | 17.56% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 83.000 K | 61.000 K | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -32.094 M | -33.816 M | -49.018 M | -67.218 M | -55.339 M | -65.021 M | |
| -5.37% | -44.96% | -37.13% | 17.67% | -17.50% |